Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 61Cisplatin 45Cetuximab 32Radiotherapy 25Nivolumab 22Docetaxel 16Radiotherapy, Intensity-Modulated 14Paclitaxel 13Carboplatin 13durvalumab 11Radiation 10Fluorouracil 10Magnetic Resonance Spectroscopy 9Cyclophosphamide 9fludarabine 8Erlotinib Hydrochloride 8budigalimab 7Ipilimumab 7atezolizumab 6Radiosurgery 6Gemcitabine 6Drug Therapy 6130-nm albumin-bound paclitaxel 6tremelimumab 5tislelizumab 5spartalizumab 5fludarabine phosphate 5avelumab 5Surgical Procedures, Operative 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Squamous Cell Carcinoma of Head and Neck × berzosertib × Clear all
NCT02567422 2026-06-02

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
43 enrolled 16 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡